Common adverse events associated with ribavirin therapy for Severe Fever with Thrombocytopenia Syndrome
作者: Qing-Bin LuShu-Yan ZhangNing CuiJian-Gong HuYa-Di FanChen-Tao GuoShu-Li QinZhen-Dong YangLi-Yuan WangHong-Yu WangXiao-Ai ZhangWei LiuWu-Chun Cao
作者单位: 1School of Public Health, Peking University, Beijing 100191, PR China
2Department of Clinical Laboratory, General Hospital of Beijing Military Region, Beijing 100700, PR China
3The 154 Hospital, People’s Liberation Army, Xinyang 464000, PR China
4State Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing 100071, PR China
5Graduate School of Anhui Medical University, Hefei 230032, PR China
刊名: Antiviral Research, 2015, Vol.119 , pp.19-22
来源数据库: Elsevier Journal
DOI: 10.1016/j.antiviral.2015.04.006
关键词: Severe Fever with Thrombocytopenia SyndromeRibavirinAdverse eventHyperamylasemia
英文摘要: Abstract(#br)Severe Fever with Thrombocytopenia Syndrome (SFTS) is associated with high mortality rate, for which antiviral therapy with ribavirin was recommended. Based on our previous study, no visible effect of ribavirin therapy in improving clinical outcome was observed. Here we have accumulated the sample size to 634, and by performing prospective observation on the clinical progress and laboratory parameters, we found a significantly higher incidence of anemia and hyperamylasemia in patients who received ribavirin therapy in comparison with those who received no therapy. Generalized estimating equation model disclosed a significant effect on hemoglobin reduction and blood amylase augmentation from ribavirin administration. The occurrence of anemia and hyperamylasemia was associated...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:3.925 (2012)

×